mTOR Inhibition for Cancer Therapy: Past, Present and Future

You must be logged in to access this title.

Sign up now

Already a member? Log in

Synopsis

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.

Book details

Edition:
1st ed. 2016
Author:
Monica Mita, Alain Mita, Eric K. Rowinsky
ISBN:
9782817804927
Related ISBNs:
9782817804910
Publisher:
Springer Paris
Pages:
N/A
Reading age:
Not specified
Includes images:
Yes
Date of addition:
2019-08-23
Usage restrictions:
Copyright
Copyright date:
2016
Copyright by:
Springer Paris, Paris 
Adult content:
No
Language:
English
Categories:
Medicine, Nonfiction, Science